Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.
(CNN) On Friday, the US Food and Drug Administration approved a new, first-of-its-kind therapy that could help patients with metastatic melanoma, a rare but deadly form of skin<a class="excerpt-read-more" href="https://wsvn.com/news/us-world/fda-approves-new-therapy-for-hard-to-treat-metastatic-melanoma/">Read More</a>
The Food and Drug Administration (FDA) announced Friday that it approved a ground breaking cellular therapy treatment for patients with advanced melanoma, and surgery has been unsuccessful. Amtagvi, a type of T-cell therapy, involves boosting immune cells within tumor tissue to help the body fight off the cancer. During the treatment, the patient’s t-cells are…
The FDA approved Amtagvi, the first cellular therapy for the treatment of adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
/PRNewswire/ Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a.